

Drug Utilization Review Board Meeting			
September 15, 2011			
Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
Follow-Up Reviews			
Emergency Contraceptive			
	Ella	NP/PA	NP/PA
Multiple Sclerosis			
	Gilenya	NP/PA	NP/PA
Anticoagulant			
	Pradaxa	NP/PA	NP/PA
Alpha-1 Proteinase Inhibitors			
	Aralast-NP Glassia Prolastin-C Zemaira	P	P/PA; PA will be implemented 1.1.12
New Drug Reviews			
Long-Acting Opioid Agonist-Antagonist			
	Butrans	NP/PA	NP/PA
Antimuscarinic			
	Cuvposa	NP/PA	NP/PA
Growth Hormone Modifier			
	Egrifta	NP/PA	NP/PA
Antihyperkinesis Agent			
	Kapvay	NP/PA	NP/PA
Ophthalmic Antihistamine			
	Lastacaft	NP/PA	NP/PA
Atypical Antipsychotics			
	Latuda	NP/PA	NP/PA
Progestin			
	Makena	NP/PA	NP/PA

Neurologic			
	Nuedexta	NP/PA	NP/PA
Antiinfective			
	Teflaro	NP/PA	NP/PA

### **Clinical Utilization Reviews**

#### Long-Acting Beta-Agonist Containing Products

Educate providers on the appropriate use of these products in the treatment of asthma as well as continue to monitor the utilization of these products and to provide a follow-up report at the June 2012 meeting.

#### Simvastatin 80mg Containing Products

Educate providers on the appropriate use of these products in the treatment of dyslipidemia as well as continue to monitor the utilization of these products and to provide a follow-up report at the June 2012 meeting.